First-line chemotherapy plus ICIs or bevacizumab in advanced non-squamous NSCLC without EGFR mutations or ALK fusions. Supplementary materials

Figure S1: Forest plots for results of pairwise meta-analyses for OS, PFS in all population.Figure S2: Network meta-analysis of specific regimens of PFS in random effect model or excluded IMpower150.Figure S3: Subgroup analysis of OS and PFS for specific regimens.Table S1: Quality assessment: risk of bias according to Cochrane Collaboration’s toolTable S2: Comparisons of the fit of consistency and inconsistency models using deviance information criteria.Table S3: Heterogeneity analysis of direct and indirect outcomes.Table S4: Rank probability of PFS for specific regimens excluded IMpower150 study.Table S5: Bayesian ranking results of network meta-analysis of different treatment models in whole population.Table S6: Bayesian ranking results of network meta-analysis of different treatment models in subgroups.Table S7: Rank probability of OS, PFS, ORR and 3-5 grade treatment related AEs for specific regimens in whole population.Table S8: Rank probability of OS and PFS for specific regimens in subgroups.Table S9: Literature search strategies